Eli D. Ehrenpreis, Chief Executive Officer at Bocaliner and Director of Research at Advocate Lutheran General Hospital Internal Medicine Residency Program, shared a post on LinkedIn about a paper by Natansh D. Modi et al. published in Cancer Medicine:
“Proton pump inhibitor (PPI) use was associated with worse outcomes in patients with breast cancer. Mechanisms may included altered gut flora or changed pharmacokinetics of chemotherapeutic drugs.
Association does not equal causation.
Also, retrospectively analyzing multiple outcomes for statistical significance is great for hypothesis testing, but without checks and balances , may be a form of data phishing.”
Title: Associations of Commonly Used Concomitant Medications With Survival and Adverse Event Outcomes in Breast Cancer
Authors: Natansh D. Modi, Ahmad Y. Abuhelwa, Nicole M. Kuderer, Lee X. Li, Gary H. Lyman, Bogda Koczwara, Ganessan Kichenadasse, Luke A. Selth, Ceara Rickard, Mark Haseloff, Agnes Vitry, Richard Woodman, Jessica M. Logan, Huah Shin Ng, Michael D. Wiese, Ross A. McKinnon, Andrew Rowland, Michael J. Sorich, Ashley M. Hopkins
You can read the Full Article in Cancer Medicine.
More posts featuring Eli D. Ehrenpreis.